Non-invasive measurement of brain damage in a primate model of multiple sclerosis

Trends in Molecular Medicine

Volumn 10, Issue 2, 2004, Pages 85-91

  'T Hart, Bert A ^a,b   Vogels, Jack ^c   Bauer, Jan ^d   Brok, Herbert P M ^a   Blezer, Erwin ^e  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c TNO   (Netherlands)

^d Brain Research Institute   (Austria)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN;

ALLERGIC ENCEPHALOMYELITIS; BRAIN INJURY; CHEMOMETRIC ANALYSIS; DEMYELINATION; DIAGNOSTIC IMAGING; HUMAN; IMMUNOPATHOLOGY; MARMOSET; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATTERN RECOGNITION; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; URINALYSIS; WHITE MATTER; X RAY ANALYSIS;

ANIMALIA; CALLITHRIX; CALLITHRIX JACCHUS; MARMOSETS; PRIMATES; RODENTIA;

EID: 1142285531     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2003.12.008     Document Type: Review

References (59)

1. Compston A., Coles A. Multiple sclerosis. Lancet. 359:2002;1221-1231.
2. Lassmann H. Neuropathology in multiple sclerosis: new concepts. Mult. Scler. 4:1998;93-98.
3. Lucchinetti C., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:2000;707-717.
4. Trapp B.D., et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:1998;278-285.
5. Brok H.P., et al. Non-human primate models of multiple sclerosis. Immunol. Rev. 183:2001;173-185.
6. Polman C.H., Uitdehaag B.M. New and emerging treatment options for multiple sclerosis. Lancet Neurol. 2:2003;563-566.
7. Bielekova B., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6:2000;1167-1175.
8. van Oosten B.W., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 47:1996;1531-1534.
9. Contag P.R. Whole-animal cellular and molecular imaging to accelerate drug development. Drug Discov. Today. 7:2002;555-562.
10. Sachs D.H. Tolerance: of mice and men. J. Clin. Invest. 111:2003;1819-1821.
11. 't Hart B.A., et al. A new primate model for multiple sclerosis in the common marmoset. Immunol. Today. 21:2000;290-297.
12. 't Hart B.A., Amor S. The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system. Curr. Opin. Neurol. 16:2003;375-383.
13. Adams A.B., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J. Clin. Invest. 111:2003;1887-1895.
14. 't Hart B.A., et al. Gene therapy in nonhuman primate models of human autoimmune disease. Gene Ther. 10:2003;890-901.
15. Marshall J.W., Ridley R.M. Assessment of cognitive and motor deficits in a marmoset model of stroke. ILAR J. 44:2003;153-160.
16. Jenner P., Marsden C.D. The actions of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in animals as a model of Parkinson's disease. J. Neural Transm. Suppl. 20:1986;11-39.
17. Baker H.F., et al. Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol. Neurobiol. 8:1994;25-39.
18. Genain C.P., Hauser S.L. Creation of a model for multiple sclerosis in Callithrix jacchus marmosets. J. Mol. Med. 75:1997;187-197.
19. Stephan H., et al. The Brain of the Common Marmoset (Callithrix jacchus). A Stereotactic Atlas. 1980;Springer Verlag.
20. Pryce C., et al. Marmosets and tamarins in biological and biomedical research. 1997;DSSD Imagery.
21. Haig D. What is a marmoset? Am. J. Primatol. 49:1999;285-296.
22. Massacesi L., et al. Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: a new model for multiple sclerosis. Ann. Neurol. 37:1995;519-530.
23. Genain C.P., et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J. Clin. Invest. 96:1995;2966-2974.
24. Genain C.P., Hauser S.L. Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus. Immunol. Rev. 183:2001;159-172.
25. Brok H.P., et al. Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule. J. Immunol. 165:2000;1093-1101.
26. Antunes S.G., et al. The common marmoset: a new world primate species with limited Mhc class II variability. Proc. Natl. Acad. Sci. U. S. A. 95:1998;11745-11750.
27. Bontrop R.E., et al. Major histocompatibility complex class II polymorphisms in primates. Immunol. Rev. 167:1999;339-350.
28. 't Hart B.A., et al. Histopathological characterization of magnetic resonance imaging- detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). Am. J. Pathol. 153:1998;649-663.
29. Mancardi G., et al. Demyelination and axonal damage in a non-human primate model of multiple sclerosis. J. Neurol. Sci. 184:2001;41-49.
30. Raine C.S., et al. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann. Neurol. 46:1999;144-160.
31. Laman J.D., et al. Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). J. Neuroimmunol. 86:1998;30-45.
32. Brok H.P., et al. An extensive monoclonal antibody panel for the phenotyping of leukocyte subsets in the common marmoset and the cotton-top tamarin. Cytometry. 45:2001;294-303.
33. von Buedingen H.C., et al. Characterization of the expressed immunoglobulin IGHV repertoire in the New World marmoset Callithrix jacchus. Immunogenetics. 53:2001;557-563.
34. de Vos A.F., et al. Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J. Immunol. 169:2002;5415-5423.
35. Genain C.P., et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5:1999;170-175.
36. McFarland H.I., et al. Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. J. Immunol. 162:1999;2384-2390.
37. 't Hart B.A., et al. The major histocompatibility complex influences the ethiopathogenesis of MS-like disease in primates at multiple levels. Hum. Immunol. 62:2001;1371-1381.
38. Yu M., et al. HLA-DP: a class II restriction molecule involved in epitope spreading during the development of multiple sclerosis. Hum. Immunol. 59:1998;15-24.
39. Barkhof F., Scheltens P. Imaging of white matter lesions. Cerebrovasc. Dis. 13:(Suppl 2):2002;21-30.
40. Jordan E.K., et al. Serial MR imaging of experimental autoimmune encephalomyelitis induced by human white matter or by chimeric myelin-basic and proteolipid protein in the common marmoset. Am. J. Neuroradiol. 20:1999;965-976.
41. Brück W., et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann. Neurol. 38:1995;788-796.
42. Bruck W., et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann. Neurol. 42:1997;783-793.
43. Brok H.P., et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J. Immunol. 169:2002;6554-6563.
44. Boon L., et al. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J. Immunol. 167:2001;2942-2949.
45. Laman J.D., et al. Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). Eur. J. Immunol. 32:2002;2218-2228.
46. Nicholson J.K., et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1:2002;153-161.
47. 't Hart B.A., et al. Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. Br. J. Rheumatol. 37:1998;314-323.
48. Brok H.P., et al. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clin. Exp. Immunol. 124:2001;134-141.
49. Giovannoni G., et al. Immunological time-course of gadolinium-enhancing MRI lesions in patients with multiple sclerosis. Eur. Neurol. 44:2000;222-228.
50. Sorensen P.S. Biological markers in body fluids for activity and progression in multiple sclerosis. Mult. Scler. 5:1999;287-290.
51. Whitaker J.N. Myelin basic protein-like material in the urine of multiple sclerosis patients: relationships to clinical and neuroimaging changes. Mult. Scler. 4:1998;243-246.
52. Cao L., et al. p-Cresol sulfate is the dominant component of urinary myelin basic protein like material. Arch. Biochem. Biophys. 377:2000;9-21.
53. 't Hart B.A., et al. 1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. J. Neurol. Sci. 212:2003;21-30.
54. Vogels J.T.W.E., et al. Partial linear fit: a new NMR spectroscopy pre-processing tool for pattern recognition applications. J. Chemometrics. 10:1996;425-438.
55. Hoogerbrugge R., et al. Discriminant analysis by double stage principal component analysis. Anal. Chem. 55:1983;1710-1712.
56. Windig W., et al. Nonsupervised numerical component extraction from pyrolysis mass spectra of complex mixtures. Anal. Chem. 56:1984;2297-2303.
57. Nicholson J.K., Wilson I.D. High resolution nuclear magnetic resonance spectroscopy of biological samples as an aid to drug development. Prog. Drug Res. 31:1987;427-479.
58. Nicholson J.K., et al. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 29:1999;1181-1189.
59. Nicholson J.K., et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1:2002;153-161.